UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 158

Sortiert nach

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Molecular cancer therapeutics, 2021-09, Vol.20 (9), p.1614-1626

2021

Volltextzugriff (PDF)

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2815-2822

2003

Volltextzugriff (PDF)

Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2831-2842

2003

Volltextzugriff (PDF)

Metabolism and disposition of dasatinib after oral administration to humans

Drug metabolism and disposition, 2008-07, Vol.36 (7), p.1357

2008

Volltextzugriff (PDF)

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Journal of clinical oncology, 2009-02, Vol.27 (4), p.526-534

2009

Volltextzugriff (PDF)

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis

NMR in biomedicine, 2002-04, Vol.15 (2), p.132-142

2002

Volltextzugriff (PDF)

Antibiotic treatment of urinary tract infection by community pharmacists: a cross-sectional study

British journal of general practice, 2013-04, Vol.63 (609), p.e244-e249

2013

Volltextzugriff (PDF)

Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3826-3840

2002

Volltextzugriff (PDF)

MR in oncology drug development

NMR in biomedicine, 2006-10, Vol.19 (6), p.681-689

Galbraith, Susan M.

2006

Volltextzugriff (PDF)

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases

Molecular cancer therapeutics, 2010-02, Vol.9 (2), p.369-378

2010

Volltextzugriff (PDF)

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (24), p.7247-7253

2002

Volltextzugriff (PDF)

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

Journal of clinical oncology, 2005-04, Vol.23 (12), p.2831-2839

2005

Volltextzugriff (PDF)

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

Clinical cancer research, 2004-03, Vol.10 (6), p.1971-1975

2004

Volltextzugriff (PDF)

Implementation of digital health technology in clinical trials: the 6R framework

Nature medicine, 2023-11, Vol.29 (11), p.2693-2697

2023

Volltextzugriff (PDF)

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Cancer discovery, 2021-08, Vol.11 (8), p.1881-1885

2021

Volltextzugriff (PDF)

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma

Journal of immunotherapy (1997), 2012-01, Vol.35 (1), p.89

2012

Volltextzugriff (PDF)

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma

Cancer immunity, 2010-11, Vol.10, p.11

2010

Volltextzugriff (PDF)

A View on Drug Development for Cancer Prevention

Cancer discovery, 2023-05, Vol.13 (5), p.1058-1083

2023

Volltextzugriff (PDF)

Diversity of US participants in AstraZeneca-sponsored clinical trials

Contemporary clinical trials, 2024-05, Vol.140, p.107496, Article 107496

2024

Volltextzugriff (PDF)

Optimization of Donor Management Goals Yields Increased Organ Use

The American surgeon, 2010-06, Vol.76 (6), p.587-594

2010

Volltextzugriff (PDF)

WEE WIN: Window of opportunity study of induction WEE1 inhibition in advanced high-grade serous ovarian cancer

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.TPS5610-TPS5610

2016

Volltextzugriff (PDF)

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high -expressing normal lung

Therapeutic advances in medical oncology, 2022-10, Vol.14

2022

Volltextzugriff (PDF)

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

Therapeutic advances in medical oncology, 2022, Vol.14, p.175883592211338-17588359221133893

2022

Volltextzugriff (PDF)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

Anticancer research, 2001-01, Vol.21 (1A), p.93

2001

Volltextzugriff (PDF)

1 – 25 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(124)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(157)
Japanisch
(21)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(98)
Life Sciences & Biomedicine
(89)
Humans
(80)
Female
(46)
Male
(41)
Biological And Medical Sciences
(30)
Medical Sciences
(26)
Oncology
(23)
Adult
(19)
Adolescent
(17)
Aged
(17)
Middle Aged
(17)
Public, Environmental & Occupational Health
(14)
Animals
(12)
Child
(12)
Pediatrics
(12)
Pharmacology. Drug Treatments
(10)
Sexual Behavior
(9)
Social Sciences
(9)
Surgery
(9)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results

Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance Imaging

Metabolism and disposition of dasatinib after oral administration to humans

Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis

Antibiotic treatment of urinary tract infection by community pharmacists: a cross-sectional study

Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging

MR in oncology drug development

The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases

ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

Implementation of digital health technology in clinical trials: the 6R framework

Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma

A View on Drug Development for Cancer Prevention

Diversity of US participants in AstraZeneca-sponsored clinical trials

Optimization of Donor Management Goals Yields Increased Organ Use

WEE WIN: Window of opportunity study of induction WEE1 inhibition in advanced high-grade serous ovarian cancer

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high -expressing normal lung

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo

Suchergebnisse filtern